Biotechnology // Browsing posts in Biotechnology
Neuronetics Idea Proposal (STIM)
Will Neuronetics’ C-suite changes, new treatment indication, expanded reimbursement, and new positive data reinvigorate growth? Report Available: November 4, 2020 Blueshift’s initial research found STIM, a leader in providing transcranial magnetic stimulation (TMS) therapy equipment and support for the treatment of Major Depressive Disorder (MDD), navigating through the coronavirus, which has had a significant […]
Slow and Steady Recovery Likely for Axogen (AXGN)
Research Question: Is the stronger-than-expected second-quarter demand Axogen experienced for its nerve regeneration products sustainable? Companies: ABBV, AXGN, HSIC, IART, SYK By: David Franklin Click here to download report (.pdf) Summary of Findings Sources were mixed trending positive regarding Axogen Inc.’s (AXGN) ability to sustain the stronger-than-expected Q2 demand for its nerve repair and […]
Axogen Idea Proposal (AXGN)
Is the stronger-than-expected Q2 demand Axogen experienced for its nerve regeneration products sustainable? Report Available: October 8, 2020 Blueshift’s initial research found AXGN, the leader in the development and commercialization of technologies for peripheral nerve regeneration and repair, experiencing a strong rebound in growth following the late Q1 and early Q2 2020 sales declines […]
Insulin Pump Market Idea Proposal (TNDM, PODD, MDT)
As the continuous glucose monitoring market continues to innovate, integrate, and grow, are insulin pump makers Tandem, Insulet, and Medtronic poised to follow? Report Available: September 3, 2020 Blueshift’s initial research found the continues glucose monitoring (CGM) market experiencing increasing demand from both Type 1 and Type 2 diabetics. The CGM space has also […]
Chembio Will Benefit from High COVID-19 Antibody Testing Demand (CEMI)
Research Question: Will Chembio’s DPP COVID-19 system gain and sustain commercial success? How will sensitivity and specificity concerns impact adoption of COVID-19 point-of-care tests? Companies: ABT, BIM.PA, CEMI, DGX, LH, RHHBY, TMO, 688298:SHA By: David Franklin Click here to download report (.pdf) Summary of Findings Chembio Diagnostics Inc.’s (CEMI) Dual Path Platform (DPP) COVID-19 […]
Chembio Diagnostics Idea Proposal (CEMI)
How will sensitivity and specificity concerns impact adoption of COVID-19 point-of-care tests? Will Chembio’s DPP COVID-19 System gain and sustain commercial success? Report Available: June 11, 2020 Blueshift’s initial research found the medical/pharma industrial complex engaging in a massive COVID-19 related effort to produce personal protective equipment, coronavirus testing systems and treatments. Over 180 […]
Sientra Inc. Set to Resume Share Gains as Plastic Surgeries Restart (SIEN)
Research Question: How will demand for Sientra’s implants for cancer and aesthetics procedures ramp post COVID-19? Will Sientra’s share gains continue? Companies: ABBV, AGN, JNJ, SIEN By: David Franklin Click here to download report (.pdf) Summary of Findings Demand for breast implant procedures is strong at plastic surgery practices reopening after COVID-19 closures, […]
Exact Sciences’ Telehealth Program a Positive Over Time (EXAS)
Research Question: What effect will Exact Sciences’ telehealth efforts have on Cologuard test numbers during and after COVID-19 quarantines? Companies: EXAS, PFE By: David Franklin Click here to download report (.pdf) Summary of Findings Exact Sciences Corp.’s (EXAS) online Cologuard ordering and telehealth program is not well known, although it is viewed positively by […]
Sientra Idea Proposal (SIEN)
How will demand for Sientra’s implants for cancer and aesthetics procedures ramp post-COVID-19? Will Sientra’s share gains continue? Report Available: May 20, 2020 Blueshift’s initial research found SIEN having to navigate a new set of challenges as elective surgeries are just now resuming. Prior to COVID-19, SIEN turned in strong Q4 2019 results with […]
Exact Sciences Idea Proposal (EXAS)
What effect will Exact Sciences’ telehealth efforts have on Cologuard test numbers during and after COVID-19 quarantines? Report Available: May 1, 2020 Prior to the COVID-19 pandemic, Blueshift’s ongoing research found EXAS turning in strong Q4 2019 results with continued growth, acquisitions, and preparing for a strong 2020. Since the coronavirus outbreak, EXAS, like […]
Copyright © 2015 Blueshift Research, LLC. All rights reserved.
